: Currently priced at $82.86 with a low P/E of 13.54; Forbes identifies it as a top energy transition play.

: Trading at $292.07, it is noted for efficient cash production and a free cash flow yield that outperforms major healthcare competitors.

: This REIT is priced at $8.60 with a forward P/E of 7.20 and expected annual earnings growth of 17%. Undervalued "Quality" Stocks

: Priced at $4.03, this biotech stock has a low forward P/E of 3.00 and projected sales growth of over 103%.

If you have a higher budget, these established companies are trading at attractive valuations compared to their long-term cash flow:

: Currently rated as significantly undervalued with a wide economic moat. Penny Stocks with High Volatility

: A defensive utility play with a 3.33% forward dividend yield.

Torna all'inizio